Cyclerion Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Cyclerion Therapeutics, Inc. files an amendment to its 2025 10-K to include Part III information and new executive certifications.
NASDAQ
Cyclerion Therapeutics, Inc. filed an amendment to its 2024 Annual Report, adding a critical audit matter regarding its investment in Tisento Therapeutics Holdings Inc. while reaffirming its going concern warning.
NASDAQ
10-K: Cyclerion Therapeutics Shifts Focus to Neuropsychiatric Diseases Amidst Going Concern Uncertainty
Cyclerion Therapeutics is pivoting towards neuropsychiatric therapeutics, particularly treatment-resistant depression, while facing substantial doubt about its ability to continue as a going concern.
NASDAQ
Cyclerion Therapeutics' 2023 10-K filing details a strategic shift away from CNS-focused sGC stimulators, the sale of key assets, and a focus on building a new portfolio.